2-甲基硫代-4,5,6,7-四氢-1H-[1,3]二氮杂卓 | 3358-41-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮卓类
• 中文名称: 2-甲基硫代-4,5,6,7-四氢-1H-[1,3]二氮杂卓
• 英文名称: 2-methylthio-4,5,6,7-tetrahydro-1H-[1,3]diazepine
• 英文别名: 2-methylthio-1,3-diaza-1-cycloheptene；2-methylsulfanyl-4,5,6,7-tetrahydro-1H-[1,3]diazepine；2-Methylmercapto-4,5,6,7-tetrahydro-1H-[1,3]diazepin；2-(methylthio)-4,5,6,7-tetrahydro-1H-1,3-diazepine；2-Methylmercapto-4,5,6,7-tetrahydro-1,3-diazepin；2-Methylthio-3,4,5,6-tetrahydro-7H-1,3-diazepin；2-methylsulfanyl-4,5,6,7-tetrahydro-1H-1,3-diazepine
• CAS: 3358-41-6
• 化学式: C₆H₁₂N₂S
• mdl: MFCD19217105
• 分子量: 144.241
• InChiKey: APZLFZUMHUZNIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  49.7
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲基硫代-4,5,6,7-四氢-1H-[1,3]二氮杂卓 在 肼 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以100%的产率得到hexahydro-1H-1,3-diazepin-2-one hydrazone hydroiodide
  参考文献：
  名称：

  [EN] TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS
  [FR] COMPOSES DE TETRAZOLE ET LEUR UTILISATION COMME ANTAGONISTES DE RECEPTEURS DE GLUTAMATE METABOTROPIQUES

  摘要：

  本发明涉及公式I的新化合物，其中P、Q、X1、X2、X3、X4、R1、R2、m和p如公式I中所定义，或其盐、溶剂合物或溶剂化盐，其制备方法及用于制备所述化合物的新中间体，含有所述化合物的药物组合物，以及所述化合物在治疗中的使用。

  公开号：

  WO2005080356A1
• 作为产物：
  描述：

  1,3-二氮杂烷-2-硫酮 在 sodium hydroxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 6.0h， 生成 2-甲基硫代-4,5,6,7-四氢-1H-[1,3]二氮杂卓
  参考文献：
  名称：

  Bogat-skii, A. V.; Luk'yanenko, N. G.; Kirichenko, T. I., Journal of Organic Chemistry USSR (English Translation), 1985, p. 1379 - 1385

  摘要：

  DOI：

文献信息

• MGluR5 modulators V
  申请人：Wallberg Andreas

  公开号：US20070259860A1

  公开（公告）日：2007-11-08

  The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

  本发明涉及新化合物，以及用于它们制备的方法，它们在治疗中的应用以及包含这些新化合物的药物组合物。
• PREPARATION AND CHEMISTRY OF Δ⁸-HEXAHYDRO-1,4,8-PYRIMIDAZOLE, Δ⁹-1,5,9-TRIAZABICYCLO(4.4.0)DECENE, AND Δ⁹-1,4,9-TRIAZABICYGLO(5.3.0)DECENE
  作者：A. F. Mckay、M.-E. Kreling

  DOI：10.1139/v57-190

  日期：1957.12.1

  The preparations of Δ⁸-hexahydro-1,4,8-pyrimidazole, Δ⁹-1,5,9-triazabicyclo(4.4.0)decene, and Δ⁹-1,4,9-triazabicyclo(5.3.0)decene from the corresponding 2-(ω-hydroxyalkylamino)-Δ²-1,3-diazacycloalkenes by chlorination and dehydrohalogenation are described. The nitro derivatives of these bicyclic compounds are more stable towards refluxing ethanol than 1-nitro-2,3,5,6-tetrahydro-1-imidaz(1,2-a)imidazole.

  Δ⁸-六氢-1,4,8-嘧啶，Δ⁹-1,5,9-三氮杂双环(4.4.0)癸烯和Δ⁹-1,4,9-三氮杂双环(5.3.0)癸烯的制备方法从相应的2-(ω-羟基烷基氨基)-Δ²-1,3-二氮杂环烯经氯化和脱卤反应得到。这些双环化合物的硝基衍生物在回流乙醇中比1-硝基-2,3,5,6-四氢-1-咪唑(1,2-a)咪唑稳定。
• Pyrimido[4,5-<i>d</i>]pyrimidin-4(1<i>H</i>)-one Derivatives as Selective Inhibitors of EGFR Threonine⁷⁹⁰to Methionine⁷⁹⁰(T790M) Mutants
  作者：Tianfeng Xu、Lianwen Zhang、Shilin Xu、Chao-Yie Yang、Jinfeng Luo、Fang Ding、Xiaoyun Lu、Yingxue Liu、Zhengchao Tu、Shiliang Li、Duanqing Pei、Qian Cai、Honglin Li、Xiaomei Ren、Shaomeng Wang、Ke Ding

  DOI：10.1002/anie.201302313

  日期：2013.8.5

  Catching the mutants: Pyrimido[4,5‐d]pyrimidin‐4(1H)‐one derivatives (see example) were identified as specific inhibitors of EGFRT790M mutants. The compounds bound with T790M or L858R/T790M mutants with significantly lower Kd values than that with EGFRWT. They also selectively inhibited EGFR signal transduction and proliferation of NSCLC cells harboring EGFRL858R/T790M mutation, but were significantly

  捕捉突变体：Pyrimido [4,5 - d ]嘧啶-4（1 H）-1衍生物（参见示例）被确定为EGFR T790M突变体的特异性抑制剂。与T790M或L858R / T790M突变体结合的化合物的K d值明显低于EGFR WT。它们还选择性抑制具有EGFR L858R / T790M突变的NSCLC细胞的EGFR信号转导和增殖，但对具有EGFR WT的细胞的效力却显着降低。
• Tautomerism of quinazolin-4-ones with 2,3-annulated hydrogenated 1,3-diazaheterocycles. Synchronous and asynchronous double proton transfer in cyclic hydrogen-bonded associates
  作者：A. S. Morkovnik、L. N. Divaeva

  DOI：10.1007/s11172-009-0111-6

  日期：2009.5

  It was shown by quantum chemical methods and 1H NMR spectroscopy that in the series of prototropic tautomeric quinazolin-4-ones with hydrogenated 1,3-diazaheterocycles annulated at positions 2 and 3, namely, imidazole, pyrimidine, or [1,3]diazepine (compounds 1–3, respectively), the 1H-tautomeric form strongly predominates in the gas phase and in solutions regardless of the nature of these cycles. Tautomerization of tricycles 1–3 occurs via the intermolecular mechanism to form as intermediates hydrogen-bonded cyclodimers of these compounds or their cyclosolvates with proton-donor solvents. The key step of the reaction is the intraassociated concerted double proton transfer, which can proceed in nearly synchronous and asynchronous modes. In particular, double proton transfer in cyclodimers of quinazolinones 1–3 is asynchronous and proceeds with the formation of solvate-stabilized polar transition states, which are similar in structure to ionic intermediates of the nonconcerted double proton transfer.

  量子化学方法和 1H NMR 光谱显示，在原向同分异构喹唑啉-4-酮系列中，氢化的 1,3-二氮杂环在第 2 位和第 3 位环化，即咪唑、嘧啶或 [1,3]diazepine（分别为化合物 1-3），无论这些循环的性质如何，1H-同分异构形式在气相和溶液中都占主导地位。三环 1-3 的同分异构反应是通过分子间机理进行的，中间产物是这些化合物的氢键环二聚体或它们与质子供体溶剂的环溶剂化物。反应的关键步骤是联合体内部协同的双质子转移，它可以以近乎同步和异步的模式进行。特别是，喹唑啉酮环二聚体 1-3 中的双质子转移是异步的，并以形成溶胶稳定的极性转变态的方式进行，这种转变态的结构与非一致双质子转移的离子中间体相似。
• Tetrazole compounds and their use as metabotropic glutamate receptor antagonists
  申请人：Johansson Martin

  公开号：US20060004021A1

  公开（公告）日：2006-01-05

  The present invention relates to new compounds of formula I, wherein P, Q, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , m and p, are as defined as in formula I, or, salts, solvates or solvated salts thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  本发明涉及式I的新化合物，其中P、Q、X1、X2、X3、X4、R1、R2、m和p如式I中所定义，或其盐、溶剂合物或溶剂化盐，其制备过程以及用于制备它们的新中间体，含有所述化合物的制药组合物以及所述化合物在治疗中的使用。